Nagler A - Search Results

1

Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.

Shimoni A, Nagler A. Shimoni A, et al. Among authors: nagler a. Cancer Treat Res. 2002;110:113-36. doi: 10.1007/978-1-4615-0919-6_6. Cancer Treat Res. 2002. PMID: 11908195 Review.

2

Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation.

Slavin S, Nagler A, Shapira MY, Aker M, Gabriel C, Or R. Slavin S, et al. Among authors: nagler a. J Clin Immunol. 2002 Mar;22(2):64-9. doi: 10.1023/a:1014423617596. J Clin Immunol. 2002. PMID: 11998894 Review.

3

Non-myeloablative stem-cell transplantation in the treatment of malignant and non-malignant disorders.

Shimoni A, Nagler A. Shimoni A, et al. Among authors: nagler a. Isr Med Assoc J. 2002 Apr;4(4):272-9. Isr Med Assoc J. 2002. PMID: 12001702 Free article. Review. No abstract available.

4

Successful major surgical recovery of a patient following haploidentical stem cell transplantation for chronic myeloid leukemia in blast crisis and aspergillosis.

Varadi G, Svirsky O, Nagler A. Varadi G, et al. Among authors: nagler a. Acta Haematol. 2002;108(1):29-32. doi: 10.1159/000063056. Acta Haematol. 2002. PMID: 12145464

5

Kröger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, Zabelina T, Fehse B, Ayuk F, Wittkowsky G, Schmitz N, Zander AR. Kröger N, et al. Among authors: nagler a. Blood. 2002 Dec 1;100(12):3919-24. doi: 10.1182/blood-2002-04-1150. Epub 2002 Aug 8. Blood. 2002. PMID: 12393448 Free article. Clinical Trial.

6

Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase.

Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, Aker M, Naparstek E, Nagler A, Slavin S. Or R, et al. Among authors: nagler a. Blood. 2003 Jan 15;101(2):441-5. doi: 10.1182/blood-2002-02-0535. Epub 2002 Sep 19. Blood. 2003. PMID: 12393604 Free article.

7

Treatment of refractory autoimmune diseases with lymphoablation and hematopoietic stem cell support.

Cohen Y, Nagler A. Cohen Y, et al. Among authors: nagler a. Isr Med Assoc J. 2002 Nov;4(11 Suppl):865-7. Isr Med Assoc J. 2002. PMID: 12455162 Review. No abstract available.

8

Treatment of refractory autoimmune diseases with ablative immunotherapy using monoclonal antibodies and/or high dose chemotherapy with hematopoietic stem cell support.

Cohen Y, Polliack A, Nagler A. Cohen Y, et al. Among authors: nagler a. Curr Pharm Des. 2003;9(3):279-88. doi: 10.2174/1381612033392134. Curr Pharm Des. 2003. PMID: 12570832 Review.

9

Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity.

Shimoni A, Bielorai B, Toren A, Hardan I, Avigdor A, Yeshurun M, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: nagler a. Exp Hematol. 2003 May;31(5):428-34. doi: 10.1016/s0301-472x(03)00047-x. Exp Hematol. 2003. PMID: 12763142 Free article.

10

Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma.

Shimoni A, Hardan I, Avigdor A, Yeshurun M, Raanani P, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: nagler a. Br J Haematol. 2003 Aug;122(3):457-64. doi: 10.1046/j.1365-2141.2003.04446.x. Br J Haematol. 2003. PMID: 12877674 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,456 results

Search Page

Filters